| Literature DB >> 30676936 |
Emmeline Ha1,2, Frederic Kim3, Janice Blanchard1, Hee-Soon Juon2,4.
Abstract
INTRODUCTION: Mongolia has the highest liver cancer incidence in the world. Hepatocellular carcinoma is the most prevalent primary liver cancer, and the most common risk factors are hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Although viral hepatitis occurs mostly in the developing world, migration of people from high prevalence countries contributes to the health outcomes of the United States. Data on Mongolian Americans is limited. The objective of this study was to estimate HBV and HCV infection prevalence among Mongolia-born immigrants living in the Washington, District of Columbia, metropolitan area.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30676936 PMCID: PMC6362705 DOI: 10.5888/pcd16.180104
Source DB: PubMed Journal: Prev Chronic Dis ISSN: 1545-1151 Impact factor: 2.830
Hepatitis Results for Mongolia-born Screening Participants (N = 634) in the Washington, District of Columbia, Metropolitan Area, 2016–2017
| Screening Result | n | % (95% Confidence Interval) |
|---|---|---|
|
| ||
| Chronic infection (HBsAg positive) | 39 | 6.2 (4.5–8.4) |
| Susceptible to infection (HBsAg negative and anti-HBs negative) | 233 | 36.8 (32.7–40.9) |
| Immune (HBsAg negative, anti-HBs positive) | 362 | 57.1 (52.7–61.4) |
|
| ||
| Exposed (anti-HCV positive and HCV RNA <15 IU/mL) | 63 | 9.9 (7.7–12.8) |
| Chronic infection (anti-HCV positive and HCV RNA ≥15 IU/mL) | 45 | 7.1 (5.6–8.9) |
| Negative (anti-HCV negative) | 571 | 90.0 (87.9–91.8) |
Abbreviations: anti-HBs, hepatitis B surface antibody; anti-HCV, hepatitis C antibody; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus.
Demographic Characteristics of Mongolia-born Screening Participants (N = 634) in the Washington, District of Columbia, Metropolitan Area, 2016–2017
| Characteristic | Total Participants, | Hepatitis B Infected | Hepatitis C Exposed | ||
|---|---|---|---|---|---|
| n (%) |
| n (%) |
| ||
|
| |||||
| 18–30 | 125 (19.7) | 8 (6.4) | .44 | 4 (3.2) | <.001 |
| 31–40 | 183 (28.9) | 10 (5.5) | 8 (4.4) | ||
| 41–50 | 198 (31.2) | 9 (4.6) | 27 (13.6) | ||
| 51–60 | 93 (14.7) | 9 (9.7) | 14 (15.1) | ||
| ≥61 | 35 (5.5) | 3 (8.6) | 10 (28.6) | ||
|
| |||||
| Female | 366 (57.7) | 25 (6.8) | .41 | 40 (10.9) | .33 |
| Male | 268 (42.3) | 14 (5.2) | 23 (8.6) | ||
|
| |||||
| <1 | 65 (10.3) | 6 (9.2) | .64 | 9 (13.9) | .26 |
| 1–5 | 253 (39.9) | 18 (7.1) | 24 (9.5) | ||
| 6–10 | 104 (16.4) | 6 (5.8) | 5 (4.8) | ||
| 11–14 | 136 (21.5) | 6 (4.4) | 17 (12.5) | ||
| ≥15 | 68 (10.7) | 3 (4.4) | 7 (10.3) | ||
|
| |||||
| English | 200 (31.6) | 8 (4.0) | .13 | 10 (5.0) | .011 |
| Mongolian | 434 (68.4) | 31 (7.1) | 53 (12.2) | ||
|
| |||||
| Yes | 70 (11.0) | 1 (1.4) | .11 | 7 (10.0) | .98 |
| No | 564 (89.0) | 38 (6.7) | 56 (9.9) | ||
|
| |||||
| Yes | 65 (10.2) | 2 (3.1) | .41 | 8 (12.3) | .50 |
| No | 569 (89.8) | 37 (6.5) | 55 (9.7) | ||
Hepatitis B surface antigen positive.
Hepatitis C antibody positive.
χ2 analysis.
Eight participants had missing data for years living in the United States, including 1 participant who was positive for hepatitis C exposure.
Fisher exact test analysis.